Liver Stiffness Screening in Metabolically Healthy Individuals

Abstract

Emerging evidence suggests that liver stiffness, measured through non-invasive modalities such as transient elastography, may identify subclinical hepatic pathology even in metabolically healthy individuals. This review explores the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, recent advances, and guideline recommendations for liver stiffness screening in this population. Emphasis is placed on the clinical significance of early detection, the underlying mechanisms linking liver stiffness to future risk, and practical implications for routine practice.

Introduction

Traditionally, liver stiffness assessment has been reserved for individuals at high risk of chronic liver disease, such as those with metabolic syndrome, viral hepatitis, or significant alcohol intake. However, recent studies have challenged the notion that metabolically healthy individuals are devoid of hepatic risk. Subtle alterations in liver tissue elasticity may precede overt disease and serve as a prognostic marker for future metabolic dysfunction, fibrosis progression, and cardiovascular events. This review aims to synthesize current evidence on liver stiffness screening in metabolically healthy subjects, highlighting the clinical rationale, available technologies, and evolving recommendations.

Epidemiology / Disease Burden

With the global rise in nonalcoholic fatty liver disease (NAFLD) and metabolic disorders, the burden of chronic liver disease has become a pressing public health concern. Although the prevalence of significant hepatic fibrosis is lower in metabolically healthy individuals compared to those with metabolic syndrome, recent population-based studies indicate a non-negligible incidence of increased liver stiffness in this group. Large-scale screening initiatives using transient elastography reveal that up to 5-10% of metabolically healthy adults may demonstrate elevated liver stiffness values, suggesting subclinical hepatic involvement even in the absence of classical risk factors. This finding underscores the need for vigilance and potential screening in selected "low-risk" populations, as early intervention may avert progression to clinically significant disease.

Pathophysiology

Liver stiffness reflects the biomechanical properties of hepatic tissue, primarily determined by extracellular matrix deposition, cellular injury, and inflammation. In metabolically healthy individuals, mechanisms contributing to increased stiffness may include low-grade inflammation, genetic susceptibility, occult steatosis, or subtle alterations in gut-liver axis dynamics. Emerging data suggest that even in the absence of overt metabolic syndrome, factors such as oxidative stress, dysregulated adipokine signaling, and microvascular changes may initiate hepatic fibrogenesis. The pathophysiological spectrum ranges from benign steatosis to early fibrosis, and liver stiffness measurement offers a window into these subclinical processes.

Risk Factors

While the absence of obesity, diabetes, and dyslipidemia defines the metabolically healthy phenotype, several risk factors may still predispose to hepatic fibrosis. These include advanced age, male sex, sedentary lifestyle, moderate alcohol consumption, genetics (e.g., PNPLA3 or TM6SF2 polymorphisms), and exposure to hepatotoxic agents. In addition, environmental factors, dietary patterns, and gut microbiota composition are increasingly recognized as modulators of liver health, even among those with favorable metabolic profiles. Identifying at-risk individuals within the metabolically healthy group is critical for targeted screening and prevention strategies.

Clinical Features

Metabolically healthy individuals with increased liver stiffness are typically asymptomatic, making clinical detection challenging. Physical examination is often unremarkable, and routine laboratory tests may not reveal significant abnormalities. However, subtle elevations in liver enzymes, particularly ALT and GGT, may be observed in a minority of cases. The absence of specific symptoms necessitates reliance on non-invasive imaging modalities for early identification of subclinical disease. Longitudinal studies indicate that elevated liver stiffness in this population is associated with increased risk of developing metabolic syndrome, diabetes, and cardiovascular disease over time.

Diagnosis

Non-invasive liver stiffness measurement, primarily via transient elastography (FibroScan), is the cornerstone of screening. This technique quantifies hepatic elasticity and has demonstrated high sensitivity and specificity for detecting significant fibrosis. Other modalities include magnetic resonance elastography (MRE) and acoustic radiation force impulse (ARFI) imaging. In metabolically healthy individuals, the positive predictive value of elevated stiffness may be lower due to the low pretest probability; thus, results must be interpreted in context. Ancillary tests such as serum fibrosis markers (e.g., FIB-4, APRI) can complement imaging findings. Liver biopsy is reserved for cases where non-invasive results are inconclusive or discordant with clinical judgment.

Treatment & Management

Management of metabolically healthy individuals with increased liver stiffness centers on risk factor modification and surveillance. Lifestyle interventions, including promoting physical activity, optimizing nutrition, and minimizing alcohol intake, are universally recommended. Pharmacologic therapies are not routinely indicated in the absence of established fibrosis or steatohepatitis but may be considered on a case-by-case basis, especially if progression is documented. Periodic reassessment of liver stiffness and metabolic risk profile is advised, as early intervention may prevent long-term complications. Multidisciplinary collaboration involving hepatology, endocrinology, and primary care enhances patient outcomes.

Recent Advances / Emerging Therapies

Recent advances in elastography technology have improved the sensitivity and reproducibility of liver stiffness measurement, enabling large-scale screening in community settings. Artificial intelligence and machine learning algorithms are being integrated into elastography software to enhance risk stratification and predictive accuracy. Novel biomarkers, including microRNAs and metabolomics signatures, are under investigation as adjuncts to imaging. Therapeutic research focuses on antifibrotic agents, gut microbiota modulation, and personalized lifestyle interventions. Ongoing clinical trials will clarify the efficacy of these strategies in preventing fibrosis progression in metabolically healthy individuals.

Guideline Recommendations

Current guidelines do not universally endorse liver stiffness screening in metabolically healthy individuals, citing insufficient evidence regarding cost-effectiveness and clinical benefit. However, expert consensus statements support consideration of screening in individuals with additional risk factors, family history of liver disease, or unexplained liver enzyme elevation. The European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) recommend individualized decision-making, emphasizing the importance of clinical context and shared decision-making with patients. Future guideline updates are anticipated as new data emerge.

Conclusion

Liver stiffness screening in metabolically healthy individuals is an evolving area of clinical practice, driven by advances in non-invasive diagnostics and a growing appreciation of subclinical hepatic risk. While the overall prevalence of significant fibrosis is low in this group, early identification of increased liver stiffness offers an opportunity for targeted intervention and prevention. A nuanced, evidence-based approach integrating risk assessment, technological advances, and individualized care will be essential as the field progresses. Ongoing research and future guideline updates will continue to shape the role of liver stiffness screening in optimizing long-term liver and metabolic health.